Organon & Co.’s Q2 2026 filing shows revenue pressures from patent expirations on key contraceptive products alongside incremental costs tied to its separation from Merck’s supply chain. The company’s strategic focus on women’s health and biosimilars provides a differentiated product portfolio across 140 countries, but many established brands face intensifying generic competition. The pending Sun Pharmaceutical merger represents a critical junction for integration and debt management, as Organon balances operational transition costs with the need to defend market share amid evolving regulatory and competitive dynamics.